应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
ZLAB 再鼎医药
交易中 03-28 11:32:28 EDT
16.24
+0.05
+0.31%
最高
16.43
最低
15.98
成交量
31.22万
今开
16.43
昨收
16.19
日振幅
2.78%
总市值
16.03亿
流通市值
14.41亿
总股本
9,872万
成交额
504.18万
换手率
0.35%
流通股本
8,872万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
再鼎医药(09688)上涨5.12%,报13.14元/股
金融界 · 10:51
再鼎医药(09688)上涨5.12%,报13.14元/股
再鼎医药下跌2.03%,报15.92美元/股
金融界 · 03-27 03:29
再鼎医药下跌2.03%,报15.92美元/股
再鼎医药(09688)下跌5.07%,报12.74元/股
金融界 · 03-22
再鼎医药(09688)下跌5.07%,报12.74元/股
南向资金3月21日净买入再鼎医药61.24万股 连续5日增持
自选股智能写手 · 03-22
南向资金3月21日净买入再鼎医药61.24万股 连续5日增持
再鼎医药盘中异动 股价大跌5.04%报17.35美元
自选股智能写手 · 03-20
再鼎医药盘中异动 股价大跌5.04%报17.35美元
南向资金3月19日净买入再鼎医药122.02万股 连续3日增持
自选股智能写手 · 03-20
南向资金3月19日净买入再鼎医药122.02万股 连续3日增持
再鼎医药上涨2.54%,报18.54美元/股
金融界 · 03-19
再鼎医药上涨2.54%,报18.54美元/股
再鼎医药下跌5.01%,报18.57美元/股
金融界 · 03-15
再鼎医药下跌5.01%,报18.57美元/股
再鼎医药盘中异动 早盘大幅跳水5.01%报18.57美元
自选股智能写手 · 03-15
再鼎医药盘中异动 早盘大幅跳水5.01%报18.57美元
再鼎医药(09688)下跌5.07%,报14.98元/股
金融界 · 03-15
再鼎医药(09688)下跌5.07%,报14.98元/股
再鼎医药盘中异动 早盘大幅下跌5.01%
自选股智能写手 · 03-14
再鼎医药盘中异动 早盘大幅下跌5.01%
再鼎医药上涨4.96%,报20.51美元/股
金融界 · 03-14
再鼎医药上涨4.96%,报20.51美元/股
再鼎医药盘中异动 股价大涨9.78%报21.45美元
自选股智能写手 · 03-13
再鼎医药盘中异动 股价大涨9.78%报21.45美元
美股开盘涨跌不一 中概创新药股集体大涨
腾讯自选股 · 03-13
美股开盘涨跌不一 中概创新药股集体大涨
南向资金3月12日净买入再鼎医药86.51万股 连续7日增持
自选股智能写手 · 03-13
南向资金3月12日净买入再鼎医药86.51万股 连续7日增持
再鼎医药下跌2.2%,报19.57美元/股
金融界 · 03-12
再鼎医药下跌2.2%,报19.57美元/股
再鼎医药盘中异动 股价大涨5.61%报19.97美元
自选股智能写手 · 03-11
再鼎医药盘中异动 股价大涨5.61%报19.97美元
南向资金3月8日净买入再鼎医药71.73万股 连续5日增持
自选股智能写手 · 03-11
南向资金3月8日净买入再鼎医药71.73万股 连续5日增持
再鼎医药(ZLAB.US/09688.HK):从2023年报来看其中长期价值
格隆汇 · 03-08
再鼎医药(ZLAB.US/09688.HK):从2023年报来看其中长期价值
再鼎医药下跌5.1%,报18.79美元/股
金融界 · 03-07
再鼎医药下跌5.1%,报18.79美元/股
加载更多
公司概况
公司名称:
再鼎医药
所属市场:
NASDAQ
上市日期:
--
主营业务:
Zai Lab Ltd是一家主要从事生物制药的控股公司该公司致力于发现或许可、开发和商业化专有疗法,以解决中国市场中大量未满足医疗需求的领域,包括肿瘤学、自身免疫和传染病。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物。其中包括Niraparib(ZL-2306)、ZL-2103和ZL-1101等。
发行价格:
--
{"stockData":{"symbol":"ZLAB","market":"US","secType":"STK","nameCN":"再鼎医药","latestPrice":16.24,"timestamp":1711639942180,"preClose":16.19,"halted":0,"volume":312166,"delay":0,"floatShares":88717931,"shares":98717523,"eps":-3.462562,"marketStatus":"交易中","marketStatusCode":2,"change":0.05,"latestTime":"03-28 11:32:28 EDT","open":16.43,"high":16.43,"low":15.98,"amount":5041823.0339359995,"amplitude":0.027795,"askPrice":16.27,"askSize":367,"bidPrice":16.23,"bidSize":207,"shortable":3,"etf":0,"ttmEps":-3.462562,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1711656000000},"adr":1,"listingDate":1505880000000,"adjPreClose":16.19,"adrRate":10,"preHourTrading":{"tag":"盘前","latestPrice":16.3,"preClose":16.19,"latestTime":"07:48 EDT","volume":1,"amount":16.3,"timestamp":1711626506623},"postHourTrading":{"tag":"盘后","latestPrice":16.19,"preClose":16.19,"latestTime":"18:46 EDT","volume":6256,"amount":101285.3184,"timestamp":1711579615329},"volumeRatio":1.209551},"requestUrl":"/m/hq/s/ZLAB","defaultTab":"news","newsList":[{"id":"2422907063","title":"再鼎医药(09688)上涨5.12%,报13.14元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2422907063","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2422907063?lang=zh_cn&edition=full","pubTime":"2024-03-28 10:51","pubTimestamp":1711594281,"startTime":"0","endTime":"0","summary":"3月28日,再鼎医药(09688)盘中上涨5.12%,截至10:51,报13.14元/股,成交1293.81万元。再鼎医药有限公司主要业务是研发和销售针对肿瘤、自身免疫性疾病、感染性疾病和中枢神经系统疾病的创新药物,以满足全球患者的医疗需求。关键经营数据方面,公司以其强大的研发能力和全球化运营策略,致力于成为全球领先的生物制药公司。截至2023年年报,再鼎医药营业总收入18.89亿元、净利润-23.7亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/03/28105140030725.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2422626782","title":"再鼎医药下跌2.03%,报15.92美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2422626782","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2422626782?lang=zh_cn&edition=full","pubTime":"2024-03-27 03:29","pubTimestamp":1711481377,"startTime":"0","endTime":"0","summary":"3月27日,再鼎医药(ZLAB)盘中下跌2.03%,截至03:29,报15.92美元/股,成交901.27万美元。财务数据显示,截至2023年12月31日,再鼎医药收入总额2.67亿美元,同比增长24.03%;归母净利润-3.35亿美元,同比增长24.51%。大事提醒:5月14日,再鼎医药将披露2024财年一季报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/03/27032940005260.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2421839434","title":"再鼎医药(09688)下跌5.07%,报12.74元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2421839434","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2421839434?lang=zh_cn&edition=full","pubTime":"2024-03-22 11:55","pubTimestamp":1711079708,"startTime":"0","endTime":"0","summary":"3月22日,再鼎医药(09688)盘中下跌5.07%,截至11:55,报12.74元/股,成交2509.86万元。再鼎医药有限公司主要业务是研发和销售针对肿瘤、自身免疫性疾病、感染性疾病和中枢神经系统疾病的创新药物,以满足全球患者的医疗需求。关键经营数据方面,公司以其强大的研发能力和全球化运营策略,致力于成为全球领先的生物制药公司。截至2023年年报,再鼎医药营业总收入18.89亿元、净利润-23.7亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/03/22115539952493.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2421815898","title":"南向资金3月21日净买入再鼎医药61.24万股 连续5日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2421815898","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2421815898?lang=zh_cn&edition=full","pubTime":"2024-03-22 09:31","pubTimestamp":1711071076,"startTime":"0","endTime":"0","summary":"3月21日, 南向资金增持再鼎医药61.24万股,连续5日增持。截止当日收盘,港股通共持有再鼎医药8382.47万股,占流通股8.44%。港股通增持金额前五个股分别为腾讯控股、中国银行、小米集团-W、中国海洋石油、小鹏汽车-W。再鼎医药近5个交易日下跌14.96%,港股通累计增持508.44万股;近20个交易日下跌14.52%,港股通累计增持862.56万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403220945568b5323e6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403220945568b5323e6&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420740123","title":"再鼎医药盘中异动 股价大跌5.04%报17.35美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2420740123","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2420740123?lang=zh_cn&edition=full","pubTime":"2024-03-20 21:37","pubTimestamp":1710941841,"startTime":"0","endTime":"0","summary":"北京时间2024年03月20日21时37分,再鼎医药股票出现波动,股价急速跳水5.04%。截至发稿,该股报17.35美元/股,成交量3.6767万股,换手率0.04%,振幅3.50%。再鼎医药股票所在的生物技术行业中,整体跌幅为0.66%。其相关个股中,Jaguar Health, Inc.、Taysha Gene Therapies, Inc.、Ocean Biomedical Inc C/Wts 14/02/2028 涨幅较大,Jaguar Health, Inc.、Tc Biopharm Plc、Nls Pharmaceutics Ltd.较为活跃,换手率分别为40.84%、30.77%、15.04%,振幅较大的相关个股有Jaguar Health, Inc.、Taysha Gene Therapies, Inc.、Design Therapeutics, Inc.,振幅分别为18.43%、18.05%、12.74%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032021372187e7a656&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032021372187e7a656&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420706737","title":"南向资金3月19日净买入再鼎医药122.02万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2420706737","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2420706737?lang=zh_cn&edition=full","pubTime":"2024-03-20 09:31","pubTimestamp":1710898288,"startTime":"0","endTime":"0","summary":"3月19日, 南向资金增持再鼎医药122.02万股,连续3日增持。截止当日收盘,港股通共持有再鼎医药8267.98万股,占流通股8.33%。再鼎医药近5个交易日下跌10.99%,港股通累计增持359.47万股;近20个交易日下跌9.29%,港股通累计增持849.21万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240320094448879a87af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240320094448879a87af&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420222453","title":"再鼎医药上涨2.54%,报18.54美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2420222453","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2420222453?lang=zh_cn&edition=full","pubTime":"2024-03-19 21:33","pubTimestamp":1710855234,"startTime":"0","endTime":"0","summary":"3月19日,再鼎医药(ZLAB)开盘上涨2.54%,截至21:33,报18.54美元/股,成交25.66万美元。财务数据显示,截至2023年12月31日,再鼎医药收入总额2.67亿美元,同比增长24.03%;归母净利润-3.35亿美元,同比增长24.51%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/03/19213339910785.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2419719903","title":"再鼎医药下跌5.01%,报18.57美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2419719903","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2419719903?lang=zh_cn&edition=full","pubTime":"2024-03-15 22:55","pubTimestamp":1710514509,"startTime":"0","endTime":"0","summary":"3月15日,再鼎医药(ZLAB)盘中下跌5.01%,截至22:55,报18.57美元/股,成交264.01万美元。财务数据显示,截至2023年12月31日,再鼎医药收入总额2.67亿美元,同比增长24.03%;归母净利润-3.35亿美元,同比增长24.51%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/03/15225539875357.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2419057889","title":"再鼎医药盘中异动 早盘大幅跳水5.01%报18.57美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2419057889","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2419057889?lang=zh_cn&edition=full","pubTime":"2024-03-15 22:54","pubTimestamp":1710514486,"startTime":"0","endTime":"0","summary":"北京时间2024年03月15日22时54分,再鼎医药股票出现异动,股价急速跳水5.01%。截至发稿,该股报18.57美元/股,成交量13.9961万股,换手率0.14%,振幅4.35%。机构评级方面,在所有11家参与评级的机构中,91%的券商给予买入建议,9%的券商给予持有建议,无券商给予卖出建议。再鼎医药股票所在的生物技术行业中,整体跌幅为0.27%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403152254477a4d17b6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403152254477a4d17b6&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2419993729","title":"再鼎医药(09688)下跌5.07%,报14.98元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2419993729","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2419993729?lang=zh_cn&edition=full","pubTime":"2024-03-15 10:27","pubTimestamp":1710469663,"startTime":"0","endTime":"0","summary":"3月15日,再鼎医药(09688)盘中下跌5.07%,截至10:27,报14.98元/股,成交1759.78万元。再鼎医药有限公司主要业务是研发和销售针对肿瘤、自身免疫性疾病、感染性疾病和中枢神经系统疾病的创新药物,以满足全球患者的医疗需求。关键经营数据方面,公司以其强大的研发能力和全球化运营策略,致力于成为全球领先的生物制药公司。截至2023年年报,再鼎医药营业总收入18.89亿元、净利润-23.7亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/03/15102739862832.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2419600361","title":"再鼎医药盘中异动 早盘大幅下跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2419600361","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2419600361?lang=zh_cn&edition=full","pubTime":"2024-03-14 21:41","pubTimestamp":1710423676,"startTime":"0","endTime":"0","summary":"北京时间2024年03月14日21时41分,再鼎医药股票出现异动,股价大幅下挫5.01%。截至发稿,该股报19.15美元/股,成交量3.6853万股,换手率0.04%,振幅2.68%。再鼎医药股票所在的生物技术行业中,整体涨幅为0.16%。其相关个股中,知临集团、180 Life Sciences Corp C/Wts 07/11/2025、Nutriband Inc C/Wts 涨幅较大,Novabay Pharmaceuticals, Inc.、知临集团、Gri Bio, Inc.较为活跃,换手率分别为126.64%、104.57%、62.17%,振幅较大的相关个股有知临集团、Nutriband Inc C/Wts 、Coherus Biosciences, Inc.,振幅分别为43.88%、26.15%、16.30%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031421411687e78f19&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031421411687e78f19&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2419634488","title":"再鼎医药上涨4.96%,报20.51美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2419634488","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2419634488?lang=zh_cn&edition=full","pubTime":"2024-03-14 00:14","pubTimestamp":1710346498,"startTime":"0","endTime":"0","summary":"3月14日,再鼎医药(ZLAB)盘中上涨4.96%,截至00:14,报20.51美元/股,成交938.78万美元。财务数据显示,截至2023年12月31日,再鼎医药收入总额2.67亿美元,同比增长24.03%;归母净利润-3.35亿美元,同比增长24.51%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/03/14001439841930.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2419684947","title":"再鼎医药盘中异动 股价大涨9.78%报21.45美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2419684947","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2419684947?lang=zh_cn&edition=full","pubTime":"2024-03-13 21:31","pubTimestamp":1710336681,"startTime":"0","endTime":"0","summary":"北京时间2024年03月13日21时31分,再鼎医药股票出现异动,股价大幅拉升9.78%。截至发稿,该股报21.45美元/股,成交量4.1727万股,换手率0.04%,振幅3.02%。再鼎医药股票所在的生物技术行业中,整体涨幅为0.34%。其相关个股中,Nucana Plc、Kintara Therapeutics, Inc.、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 涨幅较大,Kintara Therapeutics, Inc.、Nucana Plc、Revelation Biosciences, Inc.较为活跃,换手率分别为84.87%、36.59%、13.49%,振幅较大的相关个股有Kintara Therapeutics, Inc.、Nucana Plc、Forte Biosciences, Inc.,振幅分别为15.67%、14.87%、8.90%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240313213121877cbb8b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240313213121877cbb8b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2419669684","title":"美股开盘涨跌不一 中概创新药股集体大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2419669684","media":"腾讯自选股","top":-1,"share":"https://www.laohu8.com/m/news/2419669684?lang=zh_cn&edition=full","pubTime":"2024-03-13 21:30","pubTimestamp":1710336658,"startTime":"0","endTime":"0","summary":"美股三大指数开盘涨跌不一,道指涨0.19%,纳指跌0.26%。中概创新药股开盘集体走强,和黄医药涨超12%,百济神州涨超10%,再鼎医药涨超8%,据券商中国报道,今日网传一份《全链条支持创新药发展实施方案(征求意见稿)》。不过,这份文件并未获得官方证实。特斯拉跌超2%。富国银行将特斯拉评级从平配下调至低配,目标价125美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240313212832791a19ed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240313212832791a19ed&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2419688510","title":"南向资金3月12日净买入再鼎医药86.51万股 连续7日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2419688510","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2419688510?lang=zh_cn&edition=full","pubTime":"2024-03-13 09:31","pubTimestamp":1710293498,"startTime":"0","endTime":"0","summary":"3月12日, 南向资金增持再鼎医药86.51万股,连续7日增持。截止当日收盘,港股通共持有再鼎医药7908.51万股,占流通股7.97%。港股通增持金额前五个股分别为中国海洋石油、中国银行、腾讯控股、理想汽车-W、农业银行。再鼎医药近5个交易日上涨5.81%,港股通累计增持255.24万股;近20个交易日上涨5.67%,港股通累计增持473.91万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403130947538779e048&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403130947538779e048&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2418530864","title":"再鼎医药下跌2.2%,报19.57美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2418530864","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2418530864?lang=zh_cn&edition=full","pubTime":"2024-03-12 21:45","pubTimestamp":1710251128,"startTime":"0","endTime":"0","summary":"3月12日,再鼎医药(ZLAB)盘中下跌2.2%,截至21:45,报19.57美元/股,成交47.73万美元。财务数据显示,截至2023年12月31日,再鼎医药收入总额2.67亿美元,同比增长24.03%;归母净利润-3.35亿美元,同比增长24.51%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/03/12214539824200.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2418655350","title":"再鼎医药盘中异动 股价大涨5.61%报19.97美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2418655350","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2418655350?lang=zh_cn&edition=full","pubTime":"2024-03-11 21:32","pubTimestamp":1710163960,"startTime":"0","endTime":"0","summary":"北京时间2024年03月11日21时32分,再鼎医药股票出现异动,股价快速上涨5.61%。截至发稿,该股报19.97美元/股,成交量1.061万股,换手率0.01%,振幅2.75%。最近的财报数据显示,该股实现营业收入2.67亿美元,净利润-3.35亿美元,每股收益-3.46美元,毛利1.71亿美元,市盈率-5.62倍。再鼎医药股票所在的生物技术行业中,整体涨幅为0.18%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031121324079195952&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031121324079195952&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2418687323","title":"南向资金3月8日净买入再鼎医药71.73万股 连续5日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2418687323","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2418687323?lang=zh_cn&edition=full","pubTime":"2024-03-11 09:31","pubTimestamp":1710120677,"startTime":"0","endTime":"0","summary":"3月8日, 南向资金增持再鼎医药71.73万股,连续5日增持。截止当日收盘,港股通共持有再鼎医药7805.28万股,占流通股7.86%。港股通增持金额前五个股分别为腾讯控股、中国移动、中国海洋石油、美团-W、理想汽车-W。再鼎医药近5个交易日下跌6.82%,港股通累计增持258.71万股;近20个交易日下跌3.47%,港股通累计增持246.68万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240311094332876fd313&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240311094332876fd313&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2417286771","title":"再鼎医药(ZLAB.US/09688.HK):从2023年报来看其中长期价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2417286771","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2417286771?lang=zh_cn&edition=full","pubTime":"2024-03-08 11:33","pubTimestamp":1709868789,"startTime":"0","endTime":"0","summary":"随着再鼎医药已商业化产品的市场份额持续增长,研发管线的临床进展不断提速,公司正向着“到2025年底实现公司盈利”的战略目标迈进。","market":"us","thumbnail":"https://img7.gelonghui.com/column/7.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/7.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/703821","is_publish_highlight":false,"gpt_icon":0},{"id":"2417798830","title":"再鼎医药下跌5.1%,报18.79美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2417798830","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2417798830?lang=zh_cn&edition=full","pubTime":"2024-03-07 23:00","pubTimestamp":1709823621,"startTime":"0","endTime":"0","summary":"3月7日,再鼎医药(ZLAB)盘中下跌5.1%,截至23:00,报18.79美元/股,成交157.72万美元。财务数据显示,截至2023年12月31日,再鼎医药收入总额2.67亿美元,同比增长24.03%;归母净利润-3.35亿美元,同比增长24.51%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/03/07230039772891.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zailaboratory.com","stockEarnings":[{"period":"1week","weight":-0.0593},{"period":"1month","weight":-0.2287},{"period":"3month","weight":-0.4067},{"period":"6month","weight":-0.334},{"period":"1year","weight":-0.5216},{"period":"ytd","weight":-0.4076}],"compareEarnings":[{"period":"1week","weight":0.0052},{"period":"1month","weight":0.034},{"period":"3month","weight":0.0975},{"period":"6month","weight":0.2238},{"period":"1year","weight":0.3225},{"period":"ytd","weight":0.1007}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Zai Lab Ltd是一家主要从事生物制药的控股公司该公司致力于发现或许可、开发和商业化专有疗法,以解决中国市场中大量未满足医疗需求的领域,包括肿瘤学、自身免疫和传染病。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物。其中包括Niraparib(ZL-2306)、ZL-2103和ZL-1101等。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.113311},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.022208},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.100026},{"month":4,"riseRate":0.5,"avgChangeRate":0.033646},{"month":5,"riseRate":0.5,"avgChangeRate":0.025011},{"month":6,"riseRate":0.5,"avgChangeRate":0.078087},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.023267},{"month":8,"riseRate":0.666667,"avgChangeRate":0.013621},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.113197},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.064295},{"month":11,"riseRate":0.714286,"avgChangeRate":0.168146},{"month":12,"riseRate":0.571429,"avgChangeRate":-0.005362}],"exchange":"NASDAQ","name":"再鼎医药","nameEN":"Zai Lab Ltd"},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.3","shortVersion":"4.22.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再鼎医药(ZLAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再鼎医药,ZLAB,再鼎医药股票,再鼎医药股票老虎,再鼎医药股票老虎国际,再鼎医药行情,再鼎医药股票行情,再鼎医药股价,再鼎医药股市,再鼎医药股票价格,再鼎医药股票交易,再鼎医药股票购买,再鼎医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再鼎医药(ZLAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}